Dyne Therapeutics, Inc.
↗Waltham, Massachusetts, USA
Dyne Therapeutics is a clinical-stage biopharmaceutical company discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Founded in 2017, the company leverages its proprietary FORCE™ (Functionally Optimized RNA-based Chimeric Element) platform to develop targeted therapeutics that deliver to muscle and the central nervous system (CNS). Dyne's pipeline includes clinical programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. The company is headquartered in Waltham, Massachusetts and employs approximately 51-200 people.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Biotechnology
Sub-Industry:Neuromuscular Disease Therapeutics
SIZE & FINANCIALS
Employees:51-200
Revenue:$0-$50M (clinical-stage, pre-revenue)
Founded:2017
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$167.7M (pre-IPO) + $402.5M (IPO) + $275M (debt)
Investors:Atlas Venture, Forbion, MPM Capital, Vida Ventures, Surveyor Capital (Citadel), RA Capital, Wellington Management, Logos Capital, Franklin Templeton, CureDuchenne Ventures
STOCK
Exchange:NASDAQ
Ticker:DYN
Market Cap:$2.4B
PIPELINE
Stage:Phase 1/2, Phase 3
Lead Drug Stage:Phase 3 (DM1) / Phase 1/2 (DMD, seeking accelerated approval 2026)
Modalities:Antisense Oligonucleotides (ASOs), Nucleic Acid Therapeutics
Active Trials:2
Trial Phases:Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:CureDuchenne (investor and partner in rare disease focus)
COMPETITION
Position:Leader/Emerging - Strong position in myotonic dystrophy space with Phase 3 program and Breakthrough Therapy Designation; advancing DMD program with positive Phase 1/2 data
Competitors:Avidity Biosciences (AOC 1001 for DM1), Sarepta Therapeutics (Exondys 51 for DMD), Capricor Therapeutics, Wave Life Sciences, Regenxbio, PepGen, Evox Therapeutics, Lupin +1 more
LEADERSHIP
Key Executives:
John Cox - President and CEO
Erick J. Lucera - Chief Financial Officer
Doug Kerr, M.D., Ph.D., MBA - Chief Medical Officer
Johanna Friedl-Naderer - Chief Commercial Officer
Ranjan (Ron) Batra, Ph.D. - Chief Scientific Officer
Vikram (Vik) Ranade, PhD - Chief Business Officer
Clarence J. Wang - VP, Head of Data Sciences
Scientific Founders:Jason P. Rhodes, Romesh R. Subramanian
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Dyne Therapeutics, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Dyne Therapeutics, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.